journal
Journals Journal of Child and Adolescen...

Journal of Child and Adolescent Psychopharmacology

https://read.qxmd.com/read/38588580/comparing-symptoms-of-major-depression-in-youth-with-confirmed-versus-suspected-bipolar-disorder
#1
JOURNAL ARTICLE
Aaron M Silverman, Mikaela K Dimick, Jessica S Barton, Eric A Youngstrom, Benjamin I Goldstein
Background: While numerous studies have compared symptoms of major depressive episodes (MDEs) associated with bipolar disorder (BD; i.e., bipolar depression) versus major depressive disorder (MDD; i.e., unipolar depression), little is known about this topic in youth. We compared MDE symptoms in youth with BD with youth with suspected BD who have similar clinical and familial characteristics aside from having BD. Methods: MDE symptoms based on Kiddie Schedule for Affective Disorders and Schizophrenia for School Age Children (K-SADS) Depression Rating Scale items for the most severe past episode were compared in youth, ages 13-21 years, with BD ( n  = 208) versus suspected BD ( n  = 165)...
April 8, 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38536004/psychometric-properties-of-the-pans-31-item-symptom-rating-scale
#2
JOURNAL ARTICLE
Gail A Bernstein, Maroof H Khan, Rebecca L Freese, Cindy Manko, Melissa Silverman, Sana Ahmed, Bahare Farhadian, Meiqian Ma, Margo Thienemann, Tanya K Murphy, Jennifer Frankovich
Objectives: Pediatric acute-onset neuropsychiatric syndrome (PANS) is characterized by sudden onset of obsessive-compulsive disorder and/or eating restriction with associated neuropsychiatric symptoms from at least two of seven categories. The PANS 31-Item Symptom Rating Scale (PANS Rating Scale) was developed to identify and measure the severity of PANS symptoms. The objective of this study was to define the psychometric properties of the PANS Rating Scale. Methods: Children with PANS ( N  = 135) and their parents participated...
March 27, 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38502842/-correction-to-a-predictive-biomarker-model-using-quantitative-electroencephalography-in-adolescent-major-depressive-disorder-by-mcvoy-et-al-j-child-adolesc-psychopharmacol-2022-32-9-460-466-doi-10-1089-cap-2022-0041
#3
(no author information available yet)
No abstract text is available yet for this article.
March 19, 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38407930/trajectories-and-predictors-for-the-development-of-clinically-significant-weight-gain-in-children-and-adolescents-prescribed-second-generation-antipsychotics
#4
JOURNAL ARTICLE
Ning Lyu, Paul J Rowan, Susan Abughosh, Tyler J Varisco, Ying Lin, Hua Chen
Background: As many as 60% of pediatric patients taking second-generation antipsychotics (SGA) experience weight gain (antipsychotic-induced weight gain). However, the subgroup that experienced substantial weight increase was poorly understood. This study aimed to identify the development and predictors of clinically significant weight gain (CSWG) among pediatric SGA recipients. Methods: A retrospective analysis of the 2016 to 2021 IQVIA Ambulatory EMR-US database was conducted. The study cohort comprised SGA-naive patients ages 5 to 19, continuously prescribed SGA for ≥90 days...
February 26, 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38377561/-correction-to-machine-learning-identifies-smartwatch-based-physiological-biomarker-for-predicting-disruptive-behavior-in-children-a-feasibility-study-by-romanowicz-et-al-j-child-adolesc-psychopharmacol-2023-33-9-387-392-doi-10-1089-cap-2023-0038
#5
https://read.qxmd.com/read/38364180/stimulant-patterns-alone-or-with-other-psychotropic-classes-in-medicaid-insured-youth-continuously-enrolled-for-3-8-years
#6
JOURNAL ARTICLE
Daniel Zhu, Julie M Zito, James F Gardner, Heather A Young, Scott Quinlan, Angelo Elmi
Objective: Little U.S. pharmacoepidemiologic study is based on treatment during continuous enrollment for periods more than a year. This study aims to show pediatric patterns of stimulant use (alone or with other psychotropic classes) from Medicaid administrative claims data for stimulant patterns of 3- to 8-year continuous enrollees. Methods: A retrospective cohort study was derived from Medicaid enrollment, pharmacy, and diagnosis claims data (2007-2014) in a mid-Atlantic state. Youth aged 2-17 years with 3-8 years of continuous enrollment treated with stimulants were compared with a date-matched comparison group treated without stimulants...
February 16, 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38350152/response-to-chadi-a-calarge-re-effects-of-long-term-sertraline-use-on-pediatric-growth-and-development-the-sertraline-pediatric-registry-for-the-evaluation-of-safety-sprites
#7
JOURNAL ARTICLE
Francesca Kolitsopoulos, Sara Ramaker, Philip Chappell, Samuel Broderick, Warren Bao, Yuliya Lokhnygina, Scott Compton, John Orazem
No abstract text is available yet for this article.
February 13, 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38306154/longitudinal-patterns-of-community-based-treatment-utilization-among-ethnically-and-racially-diverse-adolescents-with-attention-deficit-hyperactivity-disorder
#8
JOURNAL ARTICLE
Devin M Hill, Margaret H Sibley, Mark A Stein, Xenia Leviyah
Background: Attention-deficit/hyperactivity disorder (ADHD) treatment utilization among adolescents is highly variable. This article describes pharmacological and nonpharmacological treatment utilization in a community sample of primarily Latinx and/or Black adolescents with ADHD ( N  = 218), followed longitudinally for 4 years, from early adolescence until approximately age 17 ( M  = 16.80, standard deviation = 1.65). Methods: Electronic surveys administered between 2012 and 2019 queried parent and youth reports of medication initiation, persistence, diversion, and misuse, as well as reasons for desistence...
February 2, 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38608011/switch-to-lisdexamfetamine-in-the-treatment-of-attention-deficit-disorder-at-a-psychiatric-outpatient-clinic-for-school-aged-children-a-danish-cohort-study
#9
JOURNAL ARTICLE
Nanna Roed Søndergaard, Karen Busk Nørøxe, Anders Helles Carlsen, Stine Helene Randing, Pernille Warrer, Per Hove Thomsen, Loa Clausen
Objectives: This study aimed to examine switch from first-line methylphenidate (MPH) to lisdexamfetamine (LDX) in school-aged children with attention-deficit/hyperactivity disorder (ADHD). Methods: This is a retrospective observational study based on systematic review of patient records of all children (7-13 years) diagnosed with ADHD and referred to a Danish specialized outpatient clinic. The study included 394 children switching from MPH to LDX as either second-line or third-line treatment (atomoxetine [ATX] as second-line treatment) during the study period from April 1, 2013, to November 5, 2019...
April 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38608010/clozapine-treatment-for-aggressive-behaviors-in-youths-with-neurodevelopmental-disorders
#10
JOURNAL ARTICLE
Stefano Berloffa, Gabriele Masi, Francesca Falcone, Valerio Simonelli, Antonio Narzisi, Elena Valente, Valentina Viglione, Annarita Milone, Gianluca Sesso
Objectives: The aim of this study was to assess effectiveness and tolerability of Clozapine in the treatment of aggression in youth with Neurodevelopmental Disorders. Methods: Patients were consecutively admitted at our third-level university hospital with nationwide catchment from June 2018 to October 2022, and followed up to July 2023. Eligibility criteria were as follows: (1) Autism Spectrum Disorder (ASD) and/or Intellectual Disability/Borderline Cognitive Functioning, (2) behavioral dyscontrol with physical aggression; (3) age range between 8 and 18 years; (4) clinical indication for Clozapine treatment after at least two failed trials with other Second-Generation Antipsychotics (SGAs); (5) availability of an at least 6-month-long follow-up...
April 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38608009/from-the-editor-in-chief-s-desk-advances-in-patient-centered-treatment-for-attention-deficit-hyperactivity-disorder
#11
EDITORIAL
Paul E Croarkin
No abstract text is available yet for this article.
April 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38483962/guanfacine-for-the-treatment-of-attention-deficit-hyperactivity-disorder-in-children-and-adolescents-with-down-syndrome-a-retrospective-chart-review
#12
JOURNAL ARTICLE
James H Powers, Michael Wu, Michelle Palumbo, Christopher J Keary, Christopher J McDougle, Caitlin Ravichandran, Robyn P Thom
Study Design: Retrospective case series. Objectives: The objective of this study was to provide naturalistic data on the use of guanfacine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in a clinically referred sample of youth with Down syndrome (DS). Methods: The medical records of children and adolescents with DS who received guanfacine for the treatment of ADHD from a multidisciplinary neurodevelopmental disorder clinic between September 1, 2011, and September 10, 2021, were reviewed...
March 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38483961/-letter-to-the-editor-suicide-risk-screening-practices-in-youth-with-developmental-disabilities
#13
LETTER
Jennifer Yoffe, Maria Valicenti-McDermott, Rosa Seijo
No abstract text is available yet for this article.
March 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38483960/suicide-stimulants-and-selective-serotonin-reuptake-inhibitors-a-retrospective-chart-review
#14
JOURNAL ARTICLE
Reena Thomas, Austin Sellers, Jamie L Fierstein, Mark Cavitt, Jeffrey Alvaro, Neil Goldenberg
Background: Previous studies suggest that selective serotonin reuptake inhibitors (SSRIs) may increase the risk of suicide among children and youth, although the association between suicide risk and the combination of SSRIs with other medication such as stimulants in this population remains unclear. This study explored whether the combination of SSRIs with stimulants influenced suicide risk. Methods: A retrospective cohort study was conducted at a single children's hospital campus-based ambulatory psychiatric clinic between September 1, 2017, and September 30, 2020...
March 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38483959/new-onset-psychosis-complicated-by-akathisia-and-catatonia-in-the-context-of-recent-immigration
#15
JOURNAL ARTICLE
Ron Israel, Daniel Organista, Gabrielle Hitzemann, Yasin Bez, Barbara J Coffey
No abstract text is available yet for this article.
March 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38483958/from-the-editor-in-chief-s-desk-reflecting-on-our-past-and-future
#16
EDITORIAL
Paul E Croarkin
No abstract text is available yet for this article.
March 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38252552/treatment-of-adolescent-depression-comparison-of-psychiatric-and-pediatric-settings-at-an-academic-medical-center-using-the-vitalsign-6-application
#17
JOURNAL ARTICLE
Emine Rabia Ayvaci, Abu Minhajuddin, Joshua S Elmore, Kush Yagnik, Manish K Jha, Graham J Emslie, Taryn L Mayes, Madhukar H Trivedi
Background: Similar outcomes and remission rates have been found for the treatment of depression in adults in primary and psychiatric care settings. However, comparatively little is known about how pediatric depression is managed across different settings. This study aims to address this gap by comparing depression treatment in pediatric and psychiatric settings. We hypothesized that pediatric care settings would be more likely to treat individuals with lower depression severity and would select pharmacotherapy less frequently as a treatment option...
March 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38377527/impact-of-pharmacogenomics-on-pediatric-psychotropic-medication-prescribing-in-an-ambulatory-care-setting
#18
JOURNAL ARTICLE
Erica Tonti, Yee Ming Lee, Nathan Gruenke, Janie Ferren, Danielle L Stutzman
Objective: Evidence for pharmacogenomic (PGx) guided treatment in child and adolescent psychiatry is growing. This study evaluated the impact of PGx testing on psychotropic medication prescribing in an ambulatory child and adolescent psychiatry and a developmental pediatrics clinic. Methods: This was a single-center, retrospective, descriptive analysis of patients who underwent PGx testing between January 2015 and October 2022 at a child and adolescent psychiatry clinic or developmental pediatrics clinic. The primary outcome was the proportion of patients with at least one psychotropic medication modification made 6-month posttesting that could be attributed to CYP2C19, CYP2D6, HLA-B*15:02, or HLA-A*31:01...
February 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38377526/high-probability-of-gene-drug-interactions-associated-with-medication-side-effects-in-adolescent-depression-results-from-a-randomized-controlled-trial-of-pharmacogenetic-testing
#19
RANDOMIZED CONTROLLED TRIAL
Sara Nooraeen, Paul E Croarkin, Jennifer R Geske, Julia Shekunov, Scott S Orth, Magdalena Romanowicz, Mark A Frye, Jennifer L Vande Voort
Introduction: Combinatorial pharmacogenetic testing panels are widely available in clinical practice and often separate medications into columns/bins associated with low, medium, or high probability of gene-drug interactions. The objective of the Adolescent Management of Depression (AMOD) study was to determine the clinical utility of combinatorial pharmacogenetic testing in a double-blind, randomized, controlled effectiveness study by comparing patients who had genetic testing results at time of medication initiation to those that did not have results until week 8...
February 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38377525/pharmacogenetics-in-child-and-adolescent-psychiatry-background-and-evidence-based-clinical-applications
#20
REVIEW
Salma Malik, Pragya Verma, Gualberto Ruaño, Areej Al Siaghy, Azwa Dilawar, Jeffrey R Bishop, Jeffrey R Strawn, Lisa B Namerow
The efficacy and tolerability of psychotropic medications can vary significantly among children and adolescents, and some of this variability relates to pharmacogenetic factors. Pharmacogenetics (PGx) in child and adolescent psychiatry can potentially improve treatment outcomes and minimize adverse drug reactions. This article reviews key pharmacokinetic and pharmacodynamic genes and principles of pharmacogenetic testing and discusses the evidence base for clinical decision-making concerning PGx testing. This article reviews current guidelines from the United States Food and Drug Administration (FDA), the Clinical Pharmacogenetics Implementation Consortium (CPIC), and the Dutch Pharmacogenetics Working Group (DPWG) and explores potential future directions...
February 2024: Journal of Child and Adolescent Psychopharmacology
journal
journal
20144
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.